The development of drugs for Alzheimer's disease focuses on reducing amyloid plaques in the brain, but this surrogate endpoint is known by the FDA not to be a valid clinical endpoint indicator. Additionally, there is a revolving door between Pfizer, FDA, and CDC, raising concerns about conflicts of interest.